secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-04-10T23:59:59+00:00
Accession:  0001493152-26-016179
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales
--------------------------------------------------------------------

- Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.
- Company's common stock continues to be offered at-the-market under existing shelf registration statement (Form S-3).
- A prospectus supplement was filed to increase the number of shares available for sale in the offering.
- Maxim Group remains the exclusive sales agent for the at-the-market offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-016179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer